GLP1R and type 2 diabetes mellitus: Incretin-based therapies appear to be particularly effective in Asian and Japanese patients with type 2 diabetes (who tend to have a pathophysiology of insulin deficiency rather than insulin resistance), and there is some evidence to suggest a profound underlying GLP-1 insufficiency in these patients [6–8].